Hong H Li

US Patent:

7652049, Jan 26, 2010

Filed:

Jul 1, 2005

Appl. No.:

11/173295

Inventors:

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 263/20
A61K 31/4015

US Classification:

514376, 514340, 514361, 514386, 5462714, 548125, 548224, 5483661

Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:.

US Patent:

7910592, Mar 22, 2011

Filed:

Dec 29, 2006

Appl. No.:

12/087185

Inventors:

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Christopher F. Thompson - Clark NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/497
A61K 31/427
A61K 31/422
A61K 31/506
C07D 239/02
C07D 241/02
C07D 401/02
C07D 277/02
C07D 263/02

US Classification:

51425505, 514256, 514365, 514376, 544242, 544336, 5462714, 548202, 548230

Abstract:

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

US Patent:

7915271, Mar 29, 2011

Filed:

Dec 29, 2006

Appl. No.:

12/087290

Inventors:

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4166
A61K 31/44
A61K 31/506
C07D 239/34
C07D 413/10
C07D 263/06

US Classification:

514274, 514326, 514376, 544315, 546209, 5462714, 548229

Abstract:

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

US Patent:

8440702, May 14, 2013

Filed:

Mar 28, 2011

Appl. No.:

13/073190

Inventors:

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4166
A61K 31/44
C07D 413/10

US Classification:

514340, 5462714

Abstract:

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

US Patent:

20080119476, May 22, 2008

Filed:

Jul 1, 2005

Appl. No.:

11/631821

Inventors:

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Palins NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

International Classification:

A61K 31/422
A61K 31/40
A61K 31/4166
A61K 31/427
A61K 31/4439
A61K 31/501
A61P 9/10
C07D 233/32
C07D 263/20
C07D 417/10
C07D 417/04
C07D 413/10
C07D 413/04
C07D 401/04
C07D 285/10
C07D 233/44
C07D 207/24
A61K 31/506
A61K 31/497
A61K 31/433
A61K 31/4168
A61K 31/421

US Classification:

51425205, 51425505, 514256, 514340, 514341, 514362, 514372, 514376, 514392, 514424, 514426, 544238, 544333, 544405, 5462714, 5462741, 548134, 548200, 548229, 5483235, 5483315, 548551

Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

US Patent:

20100099716, Apr 22, 2010

Filed:

Nov 25, 2009

Appl. No.:

12/625783

Inventors:

Amjad ALI - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

International Classification:

A61K 31/421
C07D 263/04
C07D 413/04
A61K 31/4439
A61P 9/10

US Classification:

514340, 548229, 5462714, 514376

Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

US Patent:

20130072492, Mar 21, 2013

Filed:

May 24, 2011

Appl. No.:

13/699046

Inventors:

Subharekha Raghavan - Teaneck NJ, US
John E. Stelmach - Westfield NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Alan Whitehead - Scotch Plains NJ, US
Sherman T. Waddell - Westfield NJ, US
Yi-Heng Chen - Whippany NJ, US
Shouwu Miao - Edison NJ, US
Olga A. Ornoski - Teaneck NJ, US
Joie Garfunkle - Metuchen NJ, US
Xibin Liao - Edison NJ, US
Jiang Chang - Westfield NJ, US
Xiaoqing Han - Edison NJ, US
Jian Guo - Scotch Plains NJ, US
Jonathan A. Groeper - Metuchen NJ, US
Linda L. Brockunier - Orange NJ, US
Keith Rosauer - New Hampton IA, US
Emma R. Parmee - Doylestown PA, US

International Classification:

C07D 487/04
C07D 495/04
A61K 31/5025
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 15/00
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
A61P 9/08
A61P 3/00
A61P 3/06
A61P 7/10
A61K 31/519

US Classification:

514248, 544280, 5142651, 544236, 51425505, 544281, 5142591

Abstract:

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

US Patent:

20230077205, Mar 9, 2023

Filed:

Jan 28, 2021

Appl. No.:

17/796023

Inventors:

- Rahway NJ, US
Hong LI - Basking Ridge NJ, US
Sketa PATEL - Parsippany NJ, US
Sandra E. RIOS - Berkely Heights NJ, US
John P. WELSH - Charlottesville VA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway

International Classification:

C07K 16/06
C07K 16/28
C12N 9/20
A61K 39/395
A61K 47/26
A61K 47/22
A61K 47/18
A61K 47/20
B01D 15/32
B01D 15/42
B01D 15/36

Abstract:

Provided herein are methods of separating host cell lipases from an anti-LAG3 antibody or antigen binding fragment in chromatographic processes and methods of improving polysorbate-80 stability in an anti-LAG3 antibody formulation by separating host cell lipases from the anti-LAG3 antibody or antigen binding fragment using chromatographic processes. Also provided are pharmaceutical compositions comprising an anti-LAG3 antibody or antigen binding fragment and less than 2 ppm of a host cell lipase.